Abstract:Abstract Background Neurocognitive impairment is present in 50% of HIV-infected individuals and is often associated with Alzheimer’s Disease (AD)-like brain pathologies, including increased amyloid-beta (Aβ) and Tau hyperphosphorylation. Here, we aimed to determine whether HIV-1 infection causes AD-like pathologies in an HIV/AIDS humanized mouse model, and whether the CCR5 antagonist maraviroc alters HIV-induced pathologies. Methods NOD/scid–IL-2Rγ c null mice engrafted with human blood leukocytes were infected with HIV-1, left untreated or treated with maraviroc (120 mg/kg twice/day). Human cells in animal’s blood were quantified weekly by flow cytometry. Animals were sacrificed at week-3 post-infection; blood and tissues viral loads were quantified using p24 antigen ELISA, RNAscope, and qPCR. Human (HLA-DR+) cells, Aβ-42, phospho-Tau, neuronal markers (MAP 2, NeuN, neurofilament-L), gamma-secretase activating protein (GSAP), and blood-brain barrier (BBB) tight junction (TJ) proteins expression and transcription were quantified in brain tissues by immunohistochemistry, immunofluorescence, immunoblotting, and qPCR. Plasma Aβ-42, Aβ-42 cellular uptake, release and transendothelial transport were quantified by ELISA. Results HIV-1 significantly decreased human (h)CD4+ T-cells and hCD4/hCD8 ratios; decreased the expression of BBB TJ proteins claudin-5, ZO-1, ZO-2; and increased HLA-DR+ cells in brain tissues. Significantly, HIV-infected animals showed increased plasma and brain Aβ-42 and phospho-Tau (threonine181, threonine231, serine396, serine199), associated with transcriptional upregulation of GSAP, an enzyme that catalyzes Aβ formation, and loss of MAP 2, NeuN, and neurofilament-L. Maraviroc treatment significantly reduced blood and brain viral loads, prevented HIV-induced loss of neuronal markers and TJ proteins; decreased HLA-DR+ cells infiltration in brain tissues, significantly reduced HIV-induced increase in Aβ-42, GSAP, and phospho-Tau. Maraviroc also reduced Aβ retention and increased Aβ release in human macrophages; decreased the receptor for advanced glycation end products (RAGE) and increased low-density lipoprotein receptor–related protein-1 (LRP1) expression in human brain endothelial cells. Maraviroc induced Aβ transendothelial transport, which was blocked by LRP1 antagonist but not RAGE antagonist. Conclusions Maraviroc significantly reduced HIV-induced amyloidogenesis, GSAP, phospho-Tau, neurodegeneration, BBB alterations, and leukocytes infiltration into the CNS. Maraviroc increased cellular Aβ efflux and transendothelial Aβ transport via LRP1 pathways. Thus, therapeutically targeting CCR5 could reduce viremia, preserve the BBB and neurons, increased brain Aβ efflux, and reduce AD-like neuropathologies.

Downregulation of CCR5 expression on cells by recombinant adenovirus containing antisense CCR5, a possible measure to prevent HIV-1 from entering target cells.

Inhibition of Expression of CCR5 and CXCR4 on Cells by Adenovirus-mediated Antisense RNA

Inhibition of CXCR4 Expression by Recombinant Adenoviruses Containing Anti-Sense RNA Resists HIV-1 Infection on MT4 Cell Lines.

Genome Editing of CXCR4 by CRISPR/cas9 Confers Cells Resistant to HIV-1 Infection.

Construction and Purification of the Recombinant Adenoviral Vector Carrying Antisense RNA to Chemokine Receptor CCR5

Chemokine Receptor Ccr5 Functionally Couples to Inhibitory G Proteins and Undergoes Desensitization

Down-regulation of CXCR4 Expression in MT4 Cells by a Recombinant Vector Expressing Antisense RNA to CXCR4 and Its Potential Anti-Hiv-1 Effect.

Regulation of Human Immunodeficiency Virus Type 1 Infection, Β-Chemokine Production, and CCR5 Expression in CD40L-Stimulated Macrophages: Immune Control of Viral Entry

Construction of Recombinant Vectors Expressing Antisense RNA to CCR5 and Expression in Eukaryotic Cells

CCR5 Editing by Staphylococcus Aureus Cas9 in Human Primary CD4+ T Cells and Hematopoietic Stem/progenitor Cells Promotes HIV-1 Resistance and CD4+ T Cell Enrichment in Humanized Mice

Therapeutic Effect of RANTES–KDEL on Inhibition of HIV-1 in CD34+ Human Hematopoietic Stem Cells (Hhsc)

Down-regulation of CXCR4 expression by SDF-KDEL in CD34+ hematopoietic stem cells: An anti-human immunodeficiency virus strategy

CCR5 Antagonist TD-0680 Uses a Novel Mechanism for Enhanced Potency Against HIV-1 Entry, Cell-mediated Infection, and a Resistant Variant

Advances of CCR5 antagonists: From small molecules to macromolecules

Genome Editing of CCR5 by AsCpf1 Renders CD4+T Cells Resistance to HIV-1 Infection

The Serum Levels and Roles of Regulated Upon Activation Normal T Cell Expressed and Secreted and Monocyte Chemoattractant Protein-1 in Human Immunodeficiency Virus-1 Infected Patients

HIV-1 Inhibition in Cells with CXCR4 Mutant Genome Created by CRISPR-Cas9 and Piggybac Recombinant Technologies.

Targeting CCR5 for anti-HIV research

124 CCR6 Ligands Inhibit HIV in Highly Susceptible CD4+CCR6+ T Cells by Inducing APOBEC3G Expression

CCR5 antagonist reduces HIV-induced amyloidogenesis, tau pathology, neurodegeneration, and blood-brain barrier alterations in HIV-infected hu-PBL-NSG mice

Effects of Lentiviral Vector-Mediated RNAi on Expression of CCR5 in CD34 + Cells in Peripheral Blood of Mice